指南与共识泌尿生殖技术与安全PET

欧洲核医学协会焦点5:前列腺癌分子影像与诊疗一体化共识

European Association of Nuclear Medicine Focus 5: Consensus on Molecular Imaging and Theranostics in Prostate Cancer.
指南 / 共识 · Eur Urol · 2023-09-22

欧洲核医学协会组织28名多学科专家,基于系统文献检索和两轮德尔菲流程,就前列腺癌分子影像与放射性配体治疗达成共识。48条陈述中42条(87.5%)达成共识,推荐PSMA PET用于多数不良中危和高危患者的分期及疑似复发患者再分期,并明确寡转移定义为最多5个转移灶。

要点

  • 推荐PSMA PET用于多数不良中危和高危前列腺癌患者的分期及疑似复发患者的再分期。
  • 共识认为即使使用先进影像学方法,寡转移性疾病也应定义为最多5个转移灶。
  • 专家组共识认为[177Lu]Lu-PSMA不应仅在进展至卡巴他赛后才使用,[223Ra]RaCl2仍是仅骨转移去势抵抗性前列腺癌的有效治疗选择。

核心结论

  • 专家组在前列腺癌分子影像与诊疗一体化应用方面达成高度共识(42/48条,87.5%),共识声明虽不能替代高确定性证据,但有助于将卓越中心的最佳实践进行解读和传播。

研究设计与样本

  • 欧洲核医学协会共识,采用系统文献检索结合两轮德尔菲流程,由28名医学或放射肿瘤学、泌尿外科、放射科、医学物理和核医学领域的前列腺癌专家参与,结果在共识会议上讨论并批准。

诊断标准与关键数值

  • 48条陈述中42条(87.5%)达成共识,共识陈述采用Likert同意量表评分,其中6条为排序选项。
  • 推荐PSMA PET用于多数不良中危和高危患者的分期以及疑似复发前列腺癌患者的再分期。
  • 寡转移性疾病应定义为最多5个转移灶,即使使用先进影像学方法。
  • 专家组共识认为[177Lu]Lu-PSMA不应仅在进展至卡巴他赛后才使用。
  • [223Ra]RaCl2仍是仅骨转移去势抵抗性前列腺癌的有效治疗选择。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 关于多个议题仍存在不确定性,包括在[177Lu]Lu-PSMA治疗前是否需要[18F]FDG和PSMA PET表现一致。
  • 共识声明不能替代高确定性证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: In prostate cancer (PCa), questions remain on indications for prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging and PSMA radioligand therapy, integration of advanced imaging in nomogram-based decision-making, dosimetry, and development of new theranostic applications.

OBJECTIVE: We aimed to critically review developments in molecular hybrid imaging and systemic radioligand therapy, to reach a multidisciplinary consensus on the current state of the art in PCa.

DESIGN, SETTING, AND PARTICIPANTS: The results of a systematic literature search informed a two-round Delphi process with a panel of 28 PCa experts in medical or radiation oncology, urology, radiology, medical physics, and nuclear medicine. The results were discussed and ratified in a consensus meeting.

OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Forty-eight statements were scored on a Likert agreement scale and six as ranking options. Agreement statements were analysed using the RAND appropriateness method. Ranking statements were analysed using weighted summed scores.

RESULTS AND LIMITATIONS: After two Delphi rounds, there was consensus on 42/48 (87.5%) of the statements. The expert panel recommends PSMA PET to be used for staging the majority of patients with unfavourable intermediate and high risk, and for restaging of suspected recurrent PCa. There was consensus that oligometastatic disease should be defined as up to five metastases, even using advanced imaging modalities. The group agreed that [177Lu]Lu-PSMA should not be administered only after progression to cabazitaxel and that [223Ra]RaCl2 remains a valid therapeutic option in bone-only metastatic castration-resistant PCa. Uncertainty remains on various topics, including the need for concordant findings on both [18F]FDG and PSMA PET prior to [177Lu]Lu-PSMA therapy.

CONCLUSIONS: There was a high proportion of agreement among a panel of experts on the use of molecular imaging and theranostics in PCa. Although consensus statements cannot replace high-certainty evidence, these can aid in the interpretation and dissemination of best practice from centres of excellence to the wider clinical community.

PATIENT SUMMARY: There are situations when dealing with prostate cancer (PCa) where both the doctors who diagnose and track the disease development and response to treatment, and those who give treatments are unsure about what the best course of action is. Examples include what methods they should use to obtain images of the cancer and what to do when the cancer has returned or spread. We reviewed published research studies and provided a summary to a panel of experts in imaging and treating PCa. We also used the research summary to develop a questionnaire whereby we asked the experts to state whether or not they agreed with a list of statements. We used these results to provide guidance to other health care professionals on how best to image men with PCa and what treatments to give, when, and in what order, based on the information the images provide.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Oprea-Lager DE, MacLennan S, Bjartell A, et al. European Association of Nuclear Medicine Focus 5: Consensus on Molecular Imaging and Theranostics in Prostate Cancer. Eur Urol. 2023. PMID: 37743194. doi:10.1016/j.eururo.2023.09.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。